AbbVieABBV

Business Snapshot

• AbbVie Inc. (NYSE: ABBV) is a U.S.-listed common stock in USD. The payload does not provide a specific sector or industry classification.
• The current pre-market price is $261.77. Over the supplied 200 daily bars, the stock rose from $230.32 to $261.77, a gain of 13.65%.
• The session range is unusually wide: $190.75–$267.47. Because the market is in pre-market status, the displayed range and price may not represent regular-session liquidity.
• No product, segment, guidance, valuation multiple, dividend, or analyst-target data was provided.

Financial Trends

• Revenue: Quarterly revenue moved from $15.776 billion in 2025-09 to $16.618 billion in 2025-12, fell to $15.002 billion in 2026-03, then accelerated to $16.990 billion in 2026-06. Latest revenue increased $1.988 billion, or 13.3%, versus Q1 2026, and is $1.214 billion, or 7.7%, above the earliest supplied period.
• Operating income and margin: Operating income rose from $1.904 billion in 2025-09 to $15.075 billion in 2025-12, dropped to $3.990 billion in 2026-03, and rebounded to $6.432 billion in 2026-06. The latest operating margin improved to 37.86% from 26.60% sequentially, a 11.26 percentage-point increase, and is well above 12.07% four periods back. The 2025-12 operating result and 90.71% margin are substantial outliers relative to the other periods.
• Net income and EPS: Net income increased from $186 million in 2025-09 to $1.816 billion in 2025-12, declined to $695 million in 2026-03, then surged to $3.613 billion in 2026-06. Latest net income rose $2.918 billion sequentially, while diluted EPS increased from $0.39 to $2.03. The latest net margin of 21.27% improved from 4.63% in Q1 2026 and 1.18% in the earliest period.
• Gross margin: Gross profit and gross margin are only supplied for 2025-12, when gross margin was 72.61%. A four-period gross-margin trajectory cannot be established.
• Free cash flow: FCF increased from $12.927 billion in 2025-09 to $17.816 billion in 2025-12, fell to $3.564 billion in 2026-03, and rebounded to $6.678 billion in 2026-06. Latest FCF improved $3.114 billion, or 87.4%, versus Q1 2026, but remains $6.249 billion, or 48.3%, below the earliest supplied period and $11.138 billion below the 2025-12 figure. This indicates recovery from the recent trough, but not a return to the strongest reported level.
• Operating cash flow and capital allocation: Operating cash flow rose from $13.812 billion in 2025-09 to $19.030 billion in 2025-12, dropped to $3.829 billion in 2026-03, and recovered to $7.265 billion in 2026-06. Capital expenditures increased from $265 million to $587 million sequentially, while financing cash flow shifted from +$919 million to -$4.135 billion, indicating materially greater cash outflow from financing in the latest period.
• Balance sheet: Total assets increased from $133.898 billion in 2025-09 to $136.463 billion in 2026-03, then declined to $135.115 billion in 2026-06. Cash rose from $5.629 billion to $9.391 billion through Q1 2026, then fell to $6.569 billion in the latest period. Inventory increased steadily from $4.938 billion to $5.127 billion.
• Liquidity and equity: The current ratio improved from 0.72 in 2025-09 to 0.81 in 2026-06, although it remains below 1.0. Working capital improved from -$10.852 billion to -$7.973 billion, but remains negative. Shareholders’ equity deteriorated from -$2.642 billion to -$5.935 billion, while retained earnings declined from -$14.234 billion to -$17.333 billion. Because equity is negative, the reported debt/equity ratios are negative and are not economically useful as conventional leverage comparisons.

Financial Health

• The latest quarter shows a clear operational rebound: revenue, operating income, net income, operating margin, and FCF all improved versus 2026-03.
• Liquidity is better than in 2025-12 and 2025-09 based on the current ratio and working capital, but the latest 0.81 current ratio and $7.973 billion of negative working capital still indicate limited short-term balance-sheet cushion.
• Cash of $6.569 billion is below the prior quarter’s $9.391 billion, coinciding with $4.135 billion of financing cash outflow. The data does not identify the specific financing uses.
• Negative shareholders’ equity worsened over the four supplied periods, from -$2.642 billion to -$5.935 billion. This weakens the balance-sheet profile despite the latest earnings and cash-flow recovery.
• The financial picture is therefore mixed: earnings and FCF are inflecting positively from the Q1 trough, while equity remains negative and liquidity remains constrained. The large quarter-to-quarter swings also warrant caution when extrapolating the latest results.

Insider Activity

• Insider sentiment is classified as Neutral (-5) for 2026-06-17 through 2026-09-15.
• Reported insider buying totaled $2.634 million across three transactions, versus $8.178 million of selling across two transactions, for net selling of $5.543 million.
• The detailed transaction shows Nicholas Donoghoe reporting a 327,100-share purchase at $79.02, valued at $2.585 million, and a 327,100-share sale at $250, valued at $8.178 million, on 2026-08-14.
• The paired buy and sale may reflect a transaction structure or transfer rather than a straightforward open-market directional purchase. Accordingly, insider data is best interpreted as neutral to mildly cautious, not as a standalone bearish signal.

Multi-Timeframe Technical Context

• Only daily data is available; minute, hourly, and other intraday timeframes are missing. Ultra-short and short-horizon conclusions are therefore lower confidence.
• Ultra-short horizon — minutes: The stock is in pre-market status, with a displayed price of $261.77 and a very broad session range of $190.75–$267.47. The daily ATR is $5.64, implying meaningful normal daily movement. A sustained move above the session high would be constructive, while a reversal toward the session low would signal substantial volatility and weak price discovery.
• Short horizon — hours to days: Price is above the 12-day EMA ($257.10), 26-day EMA ($256.10), 50-day EMA ($251.68), 20-day SMA ($258.86), and 50-day SMA ($254.52), which favors a positive near-term trend structure. Price remains below the upper Bollinger Band at $269.04, leaving nearby overhead resistance.
• Momentum is mixed: RSI-14 is 46.86, near neutral and below 50, while RSI-21 is 57.90, still moderately constructive. MACD is positive at 1.002, but below its 1.4939 signal line, indicating weakening short-term momentum despite price holding above key moving averages.
• Current volume of approximately 4.51 million is slightly above the 20-day average of approximately 4.36 million, or about 3.6% higher, providing modest confirmation but not an exceptional volume surge.
• Long horizon — weeks to months: The 200-day SMA is $228.90, well below the current price, and the 50-day SMA is above the 200-day SMA, supporting a broader upward trend. However, the stock is approaching the upper end of its recent daily range, while neutral RSI-14 and a bearish MACD crossover warn that the advance may consolidate before extending.

Bull / Bear Cases

• Short-term bull case: Holding above $257–$259 would preserve the stock’s position above its short- and intermediate-term moving averages. A decisive, volume-supported break above $267.47 could open a test of the $269.04 upper Bollinger Band. The latest financial quarter also provides a fundamental backdrop of accelerating revenue, operating margin, net income, and FCF versus Q1.
• Short-term bear case: Failure to hold the $256–$259 moving-average cluster, combined with MACD remaining below its signal line, could produce a pullback toward $251.68–$254.52, the 50-day EMA/SMA area. A break beneath that zone would weaken the near-term trend and could expose the $248.69 lower Bollinger Band.
• Long-term bull case: The latest quarter shows a positive inflection from the prior reporting period: revenue rose 13.3% sequentially, operating margin expanded 11.26 percentage points, net income increased by $2.918 billion, and FCF rose 87.4%. Continued improvement from the Q1 trough could support the longer-term thesis.
• Long-term bear case: FCF remains 48.3% below the earliest supplied period, shareholders’ equity has deteriorated to -$5.935 billion, and working capital remains negative. The large variability in operating income, net income, and cash flow makes the latest rebound difficult to treat as a stable trend without additional periods. Net insider activity is also negative, though the reported transaction is not clearly directional.

Key Levels & Triggers

• Immediate resistance: $267.47 session high.
• Secondary resistance: $269.04 upper Bollinger Band.
• Near-term support: $258.86 20-day SMA and Bollinger middle band.
• Additional support: $257.10 12-day EMA and $256.10 26-day EMA.
• Intermediate support: $254.52 50-day SMA and $251.68 50-day EMA.
• Lower technical support: $248.69 lower Bollinger Band.
• Trend reference: $228.90 200-day SMA.
• Bullish trigger: A sustained break above $267.47–$269.04 with volume above the approximately 4.36 million 20-day average would strengthen the upside continuation case.
• Bearish trigger: A close below the $251.68–$254.52 support cluster would weaken the short-term structure; a move below $248.69 would signal a deeper technical retracement.
• Fundamental trigger: Further sequential improvement in revenue, margins, and FCF would support the recovery thesis. Conversely, renewed deterioration in cash flow, current liquidity, or shareholders’ equity would reinforce the balance-sheet risks.